HHS expands access to six unproven peptides, bypassing FDA's formal review process

RFK Jr. opens the door to compounded peptides — without FDA sign-off

HHS has issued an interim enforcement policy allowing physicians, state-licensed pharmacies, and federal facilities to compound six peptides — BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500 — without FDA enforcement action. The move, championed by HHS Secretary Robert F. Kennedy Jr. as advancing "patient choice and freedom," follows a July Pharmacy Compounding Advisory Committee (PCAC) meeting but notably bypasses the formal rulemaking and public comment process that a standard FDA listing would require.

The decision has drawn sharp criticism from within the agency itself. FDA scientific staffers reportedly opposed the changes, warning the policy could undermine the FDA's core mission of keeping unsafe products off the market. Emergency medicine physician Owais Durrani, DO, acknowledged a narrow upside — compounded prescriptions are safer than unregulated overseas vials — but flagged serious concerns about long-term risks, including potential cancer implications tied to compounds that affect tissue growth and cellular aging.

Key Takeaways

• None of the six peptides are FDA-approved, and no established dosing or long-term safety data exists for any of them
• Prescribing physicians bear full responsibility for informed consent and adverse event reporting
• Patients are likely to interpret the policy as FDA endorsement — it is not
• Clinicians have the right to decline prescribing these compounds

Why it matters: This policy sets a precedent for executive-level health decisions that sidestep scientific review, putting the onus on individual clinicians to navigate patient expectations and safety risks for substances with little human evidence.